Nothing Special   »   [go: up one dir, main page]

DK1789041T3 - Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer - Google Patents

Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer

Info

Publication number
DK1789041T3
DK1789041T3 DK05776709T DK05776709T DK1789041T3 DK 1789041 T3 DK1789041 T3 DK 1789041T3 DK 05776709 T DK05776709 T DK 05776709T DK 05776709 T DK05776709 T DK 05776709T DK 1789041 T3 DK1789041 T3 DK 1789041T3
Authority
DK
Denmark
Prior art keywords
beta
aryl
pyridine derivatives
hsd1 inhibitors
hsd1
Prior art date
Application number
DK05776709T
Other languages
English (en)
Inventor
Kurt Amrein
Daniel Hunziker
Bernd Kuhn
Werner Neidhart
Alexander Mayweg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1789041T3 publication Critical patent/DK1789041T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK05776709T 2004-07-28 2005-07-20 Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer DK1789041T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103639 2004-07-28
PCT/EP2005/007894 WO2006010546A2 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors

Publications (1)

Publication Number Publication Date
DK1789041T3 true DK1789041T3 (da) 2008-09-08

Family

ID=35427898

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05776709T DK1789041T3 (da) 2004-07-28 2005-07-20 Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer

Country Status (27)

Country Link
US (2) US7528159B2 (da)
EP (1) EP1789041B1 (da)
JP (1) JP4690402B2 (da)
KR (1) KR100926842B1 (da)
CN (1) CN100589803C (da)
AR (1) AR049739A1 (da)
AT (1) ATE400271T1 (da)
AU (1) AU2005266531B2 (da)
BR (1) BRPI0513864A (da)
CA (1) CA2574875C (da)
DE (1) DE602005008079D1 (da)
DK (1) DK1789041T3 (da)
ES (1) ES2309789T3 (da)
HK (1) HK1105592A1 (da)
HR (1) HRP20080477T3 (da)
IL (1) IL180481A (da)
MX (1) MX2007000789A (da)
MY (1) MY138941A (da)
NO (1) NO20070458L (da)
NZ (1) NZ552398A (da)
PL (1) PL1789041T3 (da)
PT (1) PT1789041E (da)
RU (1) RU2374239C2 (da)
SI (1) SI1789041T1 (da)
TW (1) TW200608972A (da)
WO (1) WO2006010546A2 (da)
ZA (1) ZA200700181B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513864A (pt) * 2004-07-28 2008-05-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades
WO2006106423A2 (en) * 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
US7632838B2 (en) * 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
EP2322505A4 (en) 2008-08-29 2011-10-19 Kowa Co 1-ADAMANTYLAZETIDIN-2-ON DERIVATIVE, PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION THEREWITH
US8252781B2 (en) 2008-10-29 2012-08-28 Kowa Company, Ltd. 1,2-diazetidin-3-one derivatives and drugs containing same
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
RS53275B (en) 2009-05-15 2014-08-29 Novartis Ag ARYL-PYRIDINE AS AN ALDOSTERON SYNTHASE INHIBITOR
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8987445B2 (en) * 2011-03-16 2015-03-24 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having TRPM8 antagonistic activity
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2865071C (en) 2012-02-22 2020-06-23 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
RU2015124564A (ru) * 2012-12-10 2017-01-12 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ БЕНЗОЛСУЛЬФОНАМИДА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ RORc
CN105175323B (zh) * 2015-09-16 2017-12-22 浙江海翔药业股份有限公司 一种制备2‑(4‑乙酰胺基苯磺酰基)胺基吡啶的方法
EP3749305A1 (en) * 2018-02-05 2020-12-16 Université de Strasbourg Compounds and compositions for the treatment of pain
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
KR102418518B1 (ko) * 2020-08-05 2022-07-07 성균관대학교산학협력단 설퍼 일라이드를 이용한 n-헤테로고리의 선택적 알킬화 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703096A (en) * 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
JP2005509677A (ja) * 2001-11-22 2005-04-14 ビオヴィトルム・アクチボラゲット 1型11−ベータ−ヒドロキシステロイドデヒヒドロゲナーゼの阻害剤
JP4559078B2 (ja) * 2001-11-22 2010-10-06 ビオヴィトルム・アクチボラゲット(プブリクト) 11−ベータ−ヒドロキシステロイド脱水素酵素タイプ1のインヒビター
MXPA05001009A (es) * 2002-07-27 2005-05-16 Astrazeneca Ab Cetonas.
BRPI0513864A (pt) * 2004-07-28 2008-05-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades

Also Published As

Publication number Publication date
US7528159B2 (en) 2009-05-05
TW200608972A (en) 2006-03-16
NO20070458L (no) 2007-01-24
US20060025455A1 (en) 2006-02-02
ES2309789T3 (es) 2008-12-16
EP1789041A2 (en) 2007-05-30
RU2007107189A (ru) 2008-09-10
WO2006010546A2 (en) 2006-02-02
KR100926842B1 (ko) 2009-11-13
DE602005008079D1 (de) 2008-08-21
HK1105592A1 (en) 2008-02-22
JP2008508212A (ja) 2008-03-21
PL1789041T3 (pl) 2008-11-28
CN100589803C (zh) 2010-02-17
NZ552398A (en) 2010-08-27
US8211913B2 (en) 2012-07-03
MX2007000789A (es) 2007-03-23
HRP20080477T3 (en) 2008-12-31
CN1988905A (zh) 2007-06-27
SI1789041T1 (sl) 2008-10-31
BRPI0513864A (pt) 2008-05-20
RU2374239C2 (ru) 2009-11-27
AU2005266531A1 (en) 2006-02-02
IL180481A0 (en) 2007-06-03
ATE400271T1 (de) 2008-07-15
MY138941A (en) 2009-08-28
ZA200700181B (en) 2009-03-25
AR049739A1 (es) 2006-08-30
JP4690402B2 (ja) 2011-06-01
CA2574875C (en) 2010-09-28
WO2006010546A3 (en) 2006-04-13
IL180481A (en) 2011-05-31
KR20070026865A (ko) 2007-03-08
PT1789041E (pt) 2008-08-20
US20090149503A1 (en) 2009-06-11
AU2005266531B2 (en) 2008-11-20
CA2574875A1 (en) 2006-02-02
EP1789041B1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
LTPA2016036I1 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
DK1725553T3 (da) Tetrahydropyridoindolderivater
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
ATE540935T1 (de) Chinazolinderivate
DK1761541T3 (da) Pyrrazolo-pyrimidin-derivater
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
DK2078001T3 (da) Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
ATE417830T1 (de) Sulfonylbenzimidazolderivate
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
ATE415400T1 (de) Pyrazolopyridinderivate
NO20076678L (no) Glutamataggrekanaseinhibitorer
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer